Target Information

Target General Infomation
Target ID
T78585
Former ID
TTDR00088
Target Name
Interleukin-5
Gene Name
IL5
Synonyms
B cell differentiation factor I; Eosinophil differentiation factor; IL-5; T-cell replacing factor; TRF; IL5
Target Type
Successful
Disease Asthma; Chronic obstructive pulmonary disease; Hypereosinophilic syndrome; asthma; Eosinophilic chronic rhinosinusitis [ICD10: D72.1, J40-J44, J45]
Asthma; Chronic obstructive pulmonary disease [ICD9: 490-492, 493, 494-496; ICD10: J40-J44, J47, J45]
Asthma; Eosinophilic oesophagitis; Hypereosinophilia [ICD10: D72.1, J40-J44, J47, J45, L20]
Asthma; Eosinophilic esophagitis; Severe asthma; Loiasis [ICD10: J45, K200]
Eosinophilic asthma [ICD9: 493; ICD10: J45]
Severe asthma; Nasal polyposis [ICD9: 471, 493; ICD10: J33, J45]
Severe asthma [ICD9: 493; ICD10: J45]
Function
Factor that induces terminal differentiation of late- developing B-cells to immunoglobulin secreting cells.
BioChemical Class
Growth factor
Target Validation
T78585
UniProt ID
P05113
Sequence
MRMLLHLSLLALGAAYVYAIPTEIPTSALVKETLALLSTHRTLLIANETLRIPVPVHKNH
QLCTEEIFQGIGTLESQTVQGGTVERLFKNLSLIKKYIDGQKKKCGEERRRVNQFLDYLQ
EFLGVMNTEWIIES
Structure
1HUL; 3QT2; 3VA2
Drugs and Mode of Action
Drug(s) Mepolizumab Drug Info Approved Severe asthma; Nasal polyposis [536958], [542665]
Reslizumab Drug Info Approved Severe asthma [889440]
Benralizumab Drug Info Phase 3 Asthma; Chronic obstructive pulmonary disease [525153], [542653]
Reslizumab Drug Info Phase 3 Eosinophilic asthma [523350], [542965]
Mepolizumab Drug Info Phase 2/3 Asthma; Eosinophilic oesophagitis; Hypereosinophilia [889326], [889327], [889338], [889339], [889353], [889366], [889367], [889370], [889372], [889380], [889381], [889382], [889385], [889393], [889394], [889409], [889417], [889423], [889430], [889432], [889435], [889436]
Reslizumab Drug Info Phase 2 Asthma; Eosinophilic esophagitis; Severe asthma; Loiasis [889348], [889350], [889358], [889427], [889434]
Benralizumab Drug Info Phase 1/2 Asthma; Chronic obstructive pulmonary disease; Hypereosinophilic syndrome; asthma; Eosinophilic chronic rhinosinusitis [889397], [889422], [889428], [889429]
Modulator Benralizumab Drug Info
Mepolizumab Drug Info
Reslizumab Drug Info [889443]
Inhibitor SOPHORICOSIDE Drug Info [551217]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Hematopoietic cell lineage
T cell receptor signaling pathway
Fc epsilon RI signaling pathway
Intestinal immune network for IgA production
Asthma
Autoimmune thyroid disease
Inflammatory bowel disease (IBD)
Allograft rejection
NetPath Pathway TCR Signaling Pathway
IL2 Signaling Pathway
RANKL Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
IL4-mediated signaling events
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Glucocorticoid receptor regulatory network
IL5-mediated signaling events
AP-1 transcription factor network
PathWhiz Pathway Fc Epsilon Receptor I Signaling in Mast Cells
Reactome GPVI-mediated activation cascade
gamma signalling through PI3Kgamma
Interleukin-3, 5 and GM-CSF signaling
RAF/MAP kinase cascade
Interleukin receptor SHC signaling
WikiPathways Cytokines and Inflammatory Response
Inflammatory Response Pathway
Hematopoietic Stem Cell Differentiation
Interleukin-2 signaling
Allograft Rejection
Interleukin-3, 5 and GM-CSF signaling
References
Ref 523350ClinicalTrials.gov (NCT01290887) Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma. U.S. National Institutes of Health.
Ref 525153ClinicalTrials.gov (NCT02417961) Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home. U.S. National Institutes of Health.
Ref 536958Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53.
Ref 542653(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7674).
Ref 542665(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7685).
Ref 542965(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8091).
Ref 889326ClinicalTrials.gov (NCT00086658) Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
Ref 889327ClinicalTrials.gov (NCT00097370) Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
Ref 889338ClinicalTrials.gov (NCT00274703) An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients
Ref 889339ClinicalTrials.gov (NCT00358449) Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
Ref 889348ClinicalTrials.gov (NCT00538434) Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
Ref 889350ClinicalTrials.gov (NCT00587288) Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma
Ref 889353ClinicalTrials.gov (NCT00716651) Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome
Ref 889358ClinicalTrials.gov (NCT01111305) Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Ref 889366ClinicalTrials.gov (NCT01362244) Mepolizumab in Nasal Polyposis
Ref 889367ClinicalTrials.gov (NCT01366521) Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils
Ref 889370ClinicalTrials.gov (NCT01463644) Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
Ref 889372ClinicalTrials.gov (NCT01520051) Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations
Ref 889380ClinicalTrials.gov (NCT01691508) Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
Ref 889381ClinicalTrials.gov (NCT01691521) Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
Ref 889382ClinicalTrials.gov (NCT01691859) MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
Ref 889385ClinicalTrials.gov (NCT01842607) A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
Ref 889393ClinicalTrials.gov (NCT02105948) Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients
Ref 889394ClinicalTrials.gov (NCT02105961) Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
Ref 889397ClinicalTrials.gov (NCT02130882) Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Ref 889409ClinicalTrials.gov (NCT02377427) Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children
Ref 889417ClinicalTrials.gov (NCT02594332) Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study
Ref 889422ClinicalTrials.gov (NCT02772419) Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
Ref 889423ClinicalTrials.gov (NCT02836496) Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Ref 889427ClinicalTrials.gov (NCT02947945) Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Ref 889428ClinicalTrials.gov (NCT02968914) Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers
Ref 889429ClinicalTrials.gov (NCT03010436) Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Ref 889430ClinicalTrials.gov (NCT03021304) Study of Mepolizumab Safety Syringe in Asthmatics
Ref 889432ClinicalTrials.gov (NCT03055195) Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis
Ref 889434ClinicalTrials.gov (NCT03074942) Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab
Ref 889435ClinicalTrials.gov (NCT03085797) Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Ref 889436ClinicalTrials.gov (NCT03099096) Study of Mepolizumab Autoinjector in Asthmatics
Ref 8894402016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. doi: 10.1038/nrd.2017.14.
Ref 551217Design and synthesis of novel hydroxyalkylaminomethylchromones for their IL-5 inhibitory activity. Bioorg Med Chem. 2010 Jul 1;18(13):4625-9. doi: 10.1016/j.bmc.2010.05.028. Epub 2010 May 15.
Ref 889443The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. doi: 10.1038/nrd3792.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.